Report overview
Monoamine Oxidase (MAO) Inhibitors are the drugs that are basically utilized for treatment of depression. These drugs usually work by prevention of breakdown of the serotonin, dopamine, and norepinephrine in CNS and maintains their availability. They also possess huge risk of distributing other neurotransmitters in the brain and digestive system causing side effects. The major side effects of MAO inhibitors are high blood pressure, insomnia and weight gain.
This report contains market size and forecasts of Monoamine Oxidase Inhibitor Drugs in Global, including the following market information:
Global Monoamine Oxidase Inhibitor Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Monoamine Oxidase Inhibitor Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Isocarboxazid Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Monoamine Oxidase Inhibitor Drugs include Takeda Pharmaceutical Company Limited, Mylan N.V., GlaxoSmithKline, Merck, Teva Pharmaceutical Industries, Bausch Health, Eli Lilly and Company, OrchidPharma and Validus Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We has surveyed the Monoamine Oxidase Inhibitor Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Monoamine Oxidase Inhibitor Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Monoamine Oxidase Inhibitor Drugs Market Segment Percentages, by Type, 2021 (%)
Isocarboxazid
Phenelzine
Tranylcypromine
Others
Global Monoamine Oxidase Inhibitor Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Monoamine Oxidase Inhibitor Drugs Market Segment Percentages, by Application, 2021 (%)
Hospitals
Homecare
Specialty Clinics
Others
Global Monoamine Oxidase Inhibitor Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Monoamine Oxidase Inhibitor Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Monoamine Oxidase Inhibitor Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Monoamine Oxidase Inhibitor Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Takeda Pharmaceutical Company Limited
Mylan N.V.
GlaxoSmithKline
Merck
Teva Pharmaceutical Industries
Bausch Health
Eli Lilly and Company
OrchidPharma
Validus Pharmaceuticals
Indoco Remedies
Teikoku Pharma
H. Lundbeck
Alliance Pharma
Solvay
Cipla
Allergan
Shionogi
BioSyent
Glenmark Pharmaceuticals Limited
AstraZeneca
Johnson & Johnson Private Limited
Gedeon Richter
Luye Pharma Group
Bristol-Myers Squibb Company
